Biogen Alzheimer’s drug debate: ‘It’s the billion-dollar question: What’s going on here?
At its core, the controversy about Biogen’s Aduhelm raises a fundamental question: Did the FDA approve a drug that doesn’t help people – and if so, why?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
